Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated With Axitinib: Subgroup Analysis from TIVO-3
Meza L, McDermott D, Escudier B, Hutson T, Porta C, Verzoni E, Atkins M, Kasturi V, Pal S, Rini B. Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated With Axitinib: Subgroup Analysis from TIVO-3. The Oncologist 2022, 28: e167-e170. PMID: 36576430, PMCID: PMC10020797, DOI: 10.1093/oncolo/oyac255.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaProgression-free survivalRenal cell carcinomaTIVO-3Cell carcinomaResponse rateEvaluate PFSAdvanced renal cell carcinomaTreated with axitinibTreatment of patientsClinical efficacyIdentified patientsSubgroup analysisTivozanibAxitinibPatientsCarcinomaSorafenibTreatmentMonthsSubgroupsTrialsTherapySurvivalDrugPredictive Biomarkers of Immunotherapy Efficacy in RCC and Their Role in Non-metastatic Stages
Malhotra J, Meza L, Salgia N, Pal S. Predictive Biomarkers of Immunotherapy Efficacy in RCC and Their Role in Non-metastatic Stages. 2022, 221-227. DOI: 10.1007/978-3-030-80546-3_17.ChaptersManagement of metastatic renal cell carcinomaProgrammed death-ligand 1Renal cell carcinomaMedian survivalCell carcinomaMetastatic renal cell carcinomaDeath-ligand 1Non-metastatic stageCheckpoint inhibitorsImmunotherapy efficacySequence therapyPredictive biomarkersInterleukin-2Exploratory markersClinical practiceCarcinomaClinical judgmentSurvivalBiomarkersPrognosisTherapyPatientsEfficacy